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This analysis explored factors influencing survival of patients with primary refractory and 
relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell project. 
We analyzed data from 1,020 patients with newly diagnosed disease, enrolled between 
September 2006 and December 2015.    
Out of 937 patients who received first line treatment, 436 (47%) were identified as refractory 
and 197 (21%) as relapsed. Median time from the end of treatment to relapse was 8 months 
(range, 2-73). Overall, 75 patients (8%) were consolidated with bone marrow transplantation, 
including 12 refractory and 22 relapsed patients. After a median follow-up of 38 months (range, 
1-96) from documentation of refractory/relapse disease, 440 patients had died. The median 
overall survival was 5.8 months, and the rates of 3-yr overall survival were 21% and 28% for 
refractory and relapsed patients, respectively (p<0.001). Patients receiving or not salvage bone 
marrow transplantation had a 3-yr survival rates of 48% and 18%, respectively, (p<0.001). In a 
univariate Cox regression analysis, refractory disease was associated with a higher risk of 
death (HR=1.43, p=0.001), whereas late relapse (>12 months, HR 0.57, p=0.001) and salvage 
therapy with transplantation (HR=0.36, p<0.001) were associated with a better OS. No 
difference was found in OS with respect to histology.  
This study accurately reflects outcomes for patients treated according to standards of care 
world-wide. Results confirm that peripheral T-cell lymphomas patients had dismal outcome after 
relapse or progression. Patients with chemotherapy sensitive disease who relapsed > 12 
months might benefit from consolidative bone marrow transplantation. 
 
Trial registration: clinicaltrials.gov identifier: NCT01142674 
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INTRODUCTION   
The mature or peripheral T-cell lymphomas (PTCL) encompass a biologically and clinically 
heterogeneous group of rare neoplasia arising from post-thymic lymphocytes and represent 10-
15% of all lymphomas in Western hemisphere 1. 
PTCL patients, except for anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase 
(ALK)-positive, exhibit a poor prognosis2,3. Current treatment strategies are largely 
unsatisfactory both in first line and in the refractory/relapsed settings. First-line therapy relies on 
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and CHOP-like regimens, with 
a remission rate of 50-65% 4–6. Phase II studies demonstrated that early consolidation with high 
dose chemotherapy and stem cell rescue could improve outcome, but this approach is restricted 
to good performance status patients and chemotherapy responsive disease. For the majority of 
patients, risk of relapse remains quite high and relapsed or refractory patients have been shown 
to have a dismal outcome7,8. In the last years, there have been several studies testing novel 
therapies in this subset of patients 9.  
Two recent observational, population-base studies focused on the outcome of relapsed or 
refractory PTCL patients have been published7,8. The first one, conducted by the British 
Columbia Cancer Agency, included 208 refractory or relapsed patients diagnosed between 
1976 and 2010. The second study included 53 patients identified from Modena Cancer Registry 
with diagnosis performed between 1997 and 2010. Both showed extremely poor outcome with 
short remissions (median survival after relapse of 5.5 months and 2.5 months, respectively) and 
they confirmed that the outcome was superior in patients able to receive a transplant.  
International T-cell project is an international prospective cohort study that enrolled patients at 
74 academic centers on four continents. The data on epidemiology, clinical features, treatments 
and outcomes were collected. The purpose of the present study was to analyze clinical features 
and explore factors influencing survival of patients with primary refractory or relapsed PTCL. 
 




The T-Cell Project (TCP, NCT01142674), sponsored by the International T-Cell Lymphoma 
Project (ITCLP), was incepted in 2006, and builds on the retrospective study carried on by the 
network2. Patients with different PTCL subtypes as from the WHO 2001 or WHO 2008 
classifications1,10 were registered in the International T-cell project at initial diagnosis. TCP is a 
prospective cohort study that collected clinical and diagnostic information to better define clinical 
characteristics, therapies and prognosis for the most frequent subtypes of PTCL - i.e. PTCL not 
otherwise specified (PTCL-NOS) and Angioimmunoblastic T-cell Lymphoma (AITL) - and to 
better outline clinical characteristics and outcome of the less common PTCL subtypes 
(Extranodal NK/T-cell lymphoma; Enteropathy-type T-cell lymphoma; Hepatosplenic T-cell 
lymphoma; Peripheral gamma-delta T-cell lymphoma; Subcutaneous panniculitis-like T-cell 
lymphoma)11. Data was collected on front-line treatment, response evaluation and updated 
follow-up for at least 5 years. Also patients who did not receive any kind of treatment should be 
registered in the study. Data management was performed at the Trial Office in Modena, Italy 
(Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and 
Reggio Emilia). Registration was based on locally established histological diagnosis. A panel of 
expert hematopathologists reviewed diagnosis of 70% of all patients; about 4% could not be 
adequately classified by central reviewers and were retained in the study with the diagnosis 
made by local pathologist; finally, for 26% of cases the samples were not centralized and these 
cases were evaluated on the basis of the local diagnosis. 
The International T-cell project was conducted in compliance with the Helsinki Declaration, it 
was approved by the appropriate research Ethics Committees or Institutional Review Boards at 
each participating Institution and it required each patient to provide written informed consent 
before registration. 
Endpoints definition 
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The principal endpoint of the analysis was survival after relapse (SAR) for patients who 
relapsed, measured from date of relapse until last follow-up or death from any cause.  
Conventional response assessment after the first treatment have been adapted from the 
Standardize Response Criteria for Non-Hodgkin’s Lymphoma and from Recommendations for 
revised Response Criteria for malignant Lymphoma 12,13; assessments were done by CT-scan 
or PET-scan according to physician discretion and responses were determined by the treating 
physician. 
For the present analysis, primary refractory disease was defined as no response or progression to 
initial treatment within one month from the end of initial therapy or unsatisfactory partial remission 
(PR), i.e. a PR that at physician’s judgment was considered as inadequate for the patient, and thus 
requiring salvage therapy immediately after completion of frontline treatment. Relapsed disease was 
defined as progression at least one month from completion of front line therapy in patients who 
achieved a complete remission (CR) or a satisfactory PR. 
Statistical analysis 
Standard descriptive analyses were carried out. For a crude association analysis, categorical 
data were analyzed using the chi-square or Fisher’s exact test (two-sided) for data analysis. 
Survival curves were estimated using the Kaplan–Meier method, and compared using the log-
rank test.  
Univariate regression analyses were conducted to identify prognostic factors associated with 
SAR. Odds ratios with their 95% confidence intervals (95CI) were computed. Two-tailed P 
values <0.05 were considered statistically significant. The Stata software, version 14·0 or 
greater (StataCorp. LLC 4905 Lakeway Drive, College Station, TX 77485 USA. www.stata.com) 
was used for data analysis. 
 
RESULTS 
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From September 2006 to July 2016, 1,451 patients have been registered by 74 institutions 
world-wide. Among them, 1020 had baseline clinical data, information on first line treatment, 
response to initial therapy, time to relapse and salvage treatment available for evaluation. At the 
time of diagnosis 83 patients (8%) received only best supportive care and were excluded from 
this analysis. Out of 937 patients who received an active treatment, 633 (68%) were identified 
as refractory or relapsed patients, while 304 (32%) patients remained in complete remission. 
Among the 633 refractory/relapsed patients, 436 (69%) were classified as refractory and 197 
(31%) as relapsed patients. The median time to relapse was 8 months (range 2-73 months).  
Among the relapsed patients, 125 (63%) presented with an early relapse (≤12 months) and 72 
(37%) presented with late relapse (>12 months).  
Main baseline patients’ characteristics of refractory/relapsed patients and all of the analyzed 
subset are shown in Table 1. The median age at diagnosis of refractory patients was 59 years 
(range 18-89) and that of relapsed patients was 58 years (range 21-88). Thirty-three percent of 
refractory patients and 16% of relapsed patients had ECOG performance status >1 at 
diagnosis, respectively. As shown in Table 1, a similar number of patients with AITL and PTCL 
had refractory (AITL - 16%, PTCL, NOS - 42%) or relapsed (AITL - 21%, PTCL, NOS - 42%) 
disease. Patients with ALCL, ALK- were more likely to have refractory disease than ALCL, 
ALK+ (14% vs. 5%), but the frequency of relapsed disease was similar between both groups 
(11%, vs.7%).   
The majority of patients (844, 90%) received chemotherapy +/- radiotherapy as first line 
treatment and 75 (8%) were consolidated with high dose therapy (HDT) and hematopoietic cell 
transplantation (HCT) (Table 1). HCT was considered to be part of 1st line therapy when it was 
given within 6 weeks from the end of the induction chemotherapy; in addition, patients who 
received HCT after 6 weeks from the end of initial chemotherapy but for whom the clinician 
specified in the planned treatment schedule that HCT was going to be given as consolidation, 
and who did not receive additional salvage therapies were considered to have received HCT as 
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part of 1st line therapy as well. Of those who received HDT, 41 patients were in first remission, 
12 (3%) had refractory and 22 (11%) had relapsed disease. 
Details of salvage treatments are shown in Table 2. Overall, 99 patients (16%) received HCT as 
part of salvage treatment. Of those with refractory disease, 62% did not achieve at least a PR 
with salvage therapy and were therefore not eligible to undergo transplantation. Twenty-nine 
percent responded well to salvage therapy but were not considered candidates for a 
transplantation. In the relapsed group, likewise, most of the patients (71%) did not undergo 
transplantation. Data on the reason why patients eligible for transplant were not referred to HCT 
consolidation was not collected: the choice if to use transplantation or not relied on physician’s 
decision. 
 
Survival after relapse 
After a median follow-up of 38 months (range 1-96 months) from documentation of 
refractory/relapsed disease, 440 (70%) patients had died. The median survival after relapse 
(SAR) was 5.8 months (95CI 4.9-7.2 months) and 3-yr SAR was 23% (95CI 19-27) (Figure 2A). 
Median SAR for refractory and relapsed patients were 5 and 11 months respectively, and 3-yr 
SAR rates were similar for both groups at 21% (95CI 17-25) and 28% (95CI 21-35), respectively 
(Figure 2B). Univariate analysis showed that in the first 24 months refractory patients had a 
poorer outcome with respect to relapsed patients (HR 1.50, 95CI 1.12-1.86, p<0.001), while 
after 24 months their outcome became similar to that of the relapsed (HR 0.75, 95CI 0.34-1.64, 
P=0.470). (Figure 2B). No difference was found in outcomes for refractory/relapsed patients 
with respect to PTCL subtype, with the exception of ALCL, ALK+ (Figure 3). 
As expected, patients responding to salvage therapy who proceeded to HCT had a better 
outcome compared to patients with no response (therefore, ineligible for HCT), with 3-yr survival 
rates of 48% and 18%, respectively (p<0.001). Similarly, patients proceeding to HCT had 
TCP 1.0 Outcomes in R/R PTCL M.Bellei Mar 06, 2018 
9 
 
significantly better outcome than patients who were eligible but did not undergo HCT for any 
reason (3-yr SAR  48% and 27% (Table 3 and Figure 4). 
In a univariate Cox regression analysis, refractory disease was associated with a higher risk of 
death compared to relapsed patients (HR=1.43, 95CI 1.16-1.76, p=0.001), whereas late relapse 
compared to early relapse (HR=0.57, 95CI 0.41-0.79, p=0.001) and salvage therapy with HDT 
compared to no HDT (HR=0.36, 95% CI 0.26-0.48, p<0.001) were associated with a longer 
SAR (Table 3).  
 
DISCUSSION 
The International T-cell project represents the largest cohort of prospectively collected data on 
patients with aggressive T-cell lymphomas and accurately reflects outcomes for patients treated 
according to standards of care around the world. In the present study, we sought to analyze the 
outcomes of patients with relapsed and refractory disease after failure of first line therapy and to 
explore potential prognostic factors influencing survival, retrieved from this database. We 
demonstrated that the outcomes are worse for patients with refractory disease and that the SAR 
at 3 years for these patients was only 21%. We also found that late relapse and consolidation 
with HCT were associated with a longer survival in chemotherapy sensitive patients.  
In our analysis, refractory/relapsed patients presented a poor risk profile. Sixty-nine percent of 
failing patients were refractory to first-line treatment and 80% of refractory and 70% of relapsed 
patients had advanced stage disease at diagnosis. Fifty percent of refractory and 33% of 
relapsed patients were at high-risk according to PIT; 50% and 32% of relapsed and refractory 
patients, respectively, were at high-risk according to IPI.  
Survival was poor in our cohort, with a median SAR for refractory and relapsed patients of only 
5 and 11 months, respectively. The results from this prospective cohort confirm findings from 
other reports that refractory disease is a poor prognostic factor 7,8. While late relapse occurring 
after 12 months vs. early relapse at less than 12 months from front-line therapy was associated 
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with a longer survival, only 11% of patients were in the late relapse category, as most relapses 
occurred within one year from front-line therapy. Surprisingly, there was no difference in 
outcomes for refractory/relapsed patients with respect to PTCL subtype, suggesting that 
significant improvements are needed in treatment strategies for all subtypes of PTCL. We were 
surprised to find similar survival rates between relapsed and refractory PTCL patients at 3 years 
post completion of therapy. However, further analysis provided that within the first 24 months of 
follow up, relapsed patients had superior survival, and it is only past that time point that the 
advantage disappeared. These results suggest that within a category of relapsed patients there 
is a subgroup with biologically refractory disease and current definitions based on clinical 
responses are not sensitive enough to identify individuals that would benefit from alternative 
approaches rather than standard salvage protocols. Furthermore, only about half of the 
refractory PTCL patients exhibited clinical high-risk based on IPI or PIT scores at diagnosis. 
Emerging genome-wide analysis at diagnosis and/or relapse might overcome these restrictions 
and better guide initial and salvage therapy in near future. 
In the relapsed and refractory setting, the best chance of long term remission and best 
outcomes occurred in patients with late (>12 months) who were able to undergo HDT followed 
by HCT, with SAR at 3 years of 48%. A major problem remains that only 16% of the patients 
could proceed to this strategy as part of the salvage treatment due to refractoriness to induction 
therapy, early relapses, ineffective salvage therapies, and overall poor performance status and 
patient-specific factors. Two recent population-based retrospective studies focusing on the 
outcome of relapsed or refractory PTCL patients have been published and they reported a 
similar poor outcome (median survival after relapse of 5.5 months and 2.5 months)7,8. Likewise, 
the outcome was far superior in patients able to receive a transplant. Taken together, the 
current challenge remains to increase the response rates of induction therapies to raise the 
number of eligible patients for the most effective available curative intent treatment. Moreover, 
these results highlight the urgent need for novel agents and more effective salvage therapies.  
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Advances in understanding the biology and genetics of T-cell lymphomas have led to the 
identification of several potential novel targets14–17. Recently, four new-generation drugs have 
been approved in USA in refractory/relapsed TCL: pralatrexate (antifolate), romidepsin and 
belinostat (histone deacetylase inhibitor), and brentuximab vedotin. In addition to these 
approved drugs, a number of novel drugs with different mechanisms are under investigation: 
crizotinib (oral tyrosine kinase inhibitor of ALK), mogamulizumab, duvelisib, plitidepsin, and 
selinexor 9,18. Hopefully, these agents will have an impact both combined with front line 
chemotherapy as well as in the relapsed and refractory setting. 
Although patient’s cohort could be not completely homogeneous (Investigators were requested 
to register consecutive cases satisfying Inclusion criteria without selection), the amplitude of the 
International T-cell Project reflects the real-world scenario, obtained through a multi-national 
database describing the distribution of PTCL subtypes and therapeutic outcomes with standard 
therapies. Our results complement those of the COMPLETE registry (NCT01110733), a similar 
prospective study of PTCL patients in the United States. These results will provide a useful 
baseline on which to assess the efficacy of novel agents and therapies for refractory/relapsed 
patients with T-cell lymphomas. Clinical trials are underway exploring the activity of novel 
agents in combination with chemotherapy to improve overall response in the front line, and 
single agent and combination studies of novel agents are underway for patients with 
refractory/relapsed disease.  
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 N % N % N % 
Median age (range), Years 59 (18-89) 58 (21-88) 56 (18-89) 
Age, >60 years, N, % 203 47 90 46 401 43 
Gender, Male, N, % 273 63 136 69 579 62 
ECOG-PS, >1, N, % 143 33 31 16 214 23 
Serum LDH, > ULN, N, % [578] 234 54 82 42 404 43 
Ann-Arbor Stage, III-IV, N, % [591] 325 75 128 65 605 65 
ENS, >1, N, % [568] 148 34 43 22 250 27 
Serum Albumin, <3.5 g/dL, N, % [562] 204 47 70 36 359 38 
NLR, >6.5, N, % [598] 125 29 48 24 231 25 
PIT, High-risk (2-4), N, % [503] 172 39 52 26 283 30 
IPI, High-risk (3-5), N, % [551] 184 42 53 27 294 31 
Histology Subtype        
PTCL, NOS 185 42 83 42 346 37 
AITL 70 16 42 21 154 16 
ALCL, ALK - 60 14 22 11 140 15 
ALCL, ALK + 21 5 14 7 77 8 
NKTCL 35 8 21 11 109 12 
Other 65 15 15 8 80 9 
1st line Therapy       
CHT +/- RT 422 97 174 88 844 90 
RT alone 2 <1 1 <1 18 2 
CHT/consolidation HDT 12 3 22 11 75 8 
Response to 1st line Therapy       
CR - - 170 86 474 51 
PR 137 31 27 14 164 18 
<PR 299 69 - - 299 32 
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 N % N % N % 
Type of event       
Relapse after CR - - 170 86 170 27 
Relapse after PR - - 27 14 27 4 
Unsatisfactory PR 137 31 - - 137 22 
Refractory (<PR) 299 69 - - 299 47 
Timing of events       
Refractory 436 69 - - 436 69 
Early relapse (≤ 12 months) - - 125 20 125 20 
Late relapse (>12 months) - - 72 11 72 11 
HCT as Salvage       
HCT, yes 42 9 57 29 99 16 
No HCT (eligible for HDT) - - 124 63   
No HCT (CR/PR not eligible to HDT) 125 29 16 8   
No HCT (<PR not eligible to HDT) 269 62 - -   
No HCT (whichever the reason) 394 91 140 71 534 84 
CR: complete remission; PR: partial remission; Unsatisfactory PR: PR requiring immediate treatment after initial therapy; HCT: 
hematopoietic cell transplantation. 
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Table 3. Univariate Cox regression analysis for SAR. 







Early relapse (≤ 12 months) 





Not eligible to HCT <PR 
Not eligible to HCT (CR/PR) 










No HCT at salvage 














Figure 1: Flow chart of patients included in the analysis. 
 
Figure 2: Survival After Relapse: Panel A, SAR curve of 633 refractory/relapsed patients; Panel 
B: SAR by status refractory vs. relapse. 
 
Figure 3. Outcomes for refractory/relapsed patients depending on histological subtypes. 
 
Figure 4: Survival After Relapse by salvage therapy (HCT vs. no-HCT). 
 
 




